TY - JOUR
TI - Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis
AU - Oikonomou, T.
AU - Goulis, I.
AU - Ntogramatzi, F.
AU - Athanasiadou, Z.
AU - Vagdatli, E.
AU - Akriviadis, E.
AU - Cholongitas, E.
JO - Digestive and Liver Disease
PY - 2019
VL - 51
TODO - 12
SP - 1692-1697
PB - Elsevier B.V.
SN - 1590-8658
TODO - 10.1016/j.dld.2019.05.030
TODO - albumin;  bilirubin;  creatinine;  edetate chromium cr 51;  galectin 3;  galectin 3, adult;  albumin blood level;  Article;  bilirubin blood level;  cohort analysis;  controlled study;  creatinine blood level;  decompensated liver cirrhosis;  disease marker;  female;  glomerulus filtration rate;  human;  Kaplan Meier method;  kidney function;  major clinical study;  male;  Model For End Stage Liver Disease Score;  priority journal;  prognosis;  prospective study;  protein blood level;  survival time;  treatment outcome;  blood;  chronic kidney failure;  complication;  deterioration;  Greece;  liver cirrhosis;  middle aged;  mortality;  pathophysiology;  predictive value, Clinical Deterioration;  Correlation of Data;  Female;  Galectin 3;  Glomerular Filtration Rate;  Greece;  Humans;  Kaplan-Meier Estimate;  Liver Cirrhosis;  Male;  Middle Aged;  Predictive Value of Tests;  Prognosis;  Renal Insufficiency, Chronic
TODO - Background: Newly introduced galectin-3 (gal-3) has been associated to impaired renal function. Gal-3 may become prognostic biomarker in hepatic diseases. Aim: To investigate the association of gal-3 with prognosis and renal function in patients with stable decompensated cirrhosis. Method: We studied prospectively 100 stable decompensated patients in our Department between 2010 and 2017. We measured gal-3 in serum samples. Patients’ renal function was assessed using 51Chromium-EDTA (“true GFR”). Results: Seventy patients (70%) survived and 30 died (n = 16) or underwent LT (n = 14). Twenty nine patients (29%) had normal gal-3, 71 (71%) had ≥11.7 ng/mL; they differed significantly regarding mean “true”-GFR: 90 ± 20 mL/min vs. 76 ± 26 mL/min, p = 0.03 and mean creatinine: 0.83 ± 0.14 mg/dL vs. 0.97 ± 0.4 mg/dL, p = 0.05. Median gal-3 levels were 17.5 ng/mL (range 4.9–76.5 ng/mL); 49 patients with gal-3 ≥17.5 ng/mL had significantly higher MELD score, (15 ± 5 vs. 13 ± 4, p = 0.02) and worse “true” GFR (74 vs. 85 mL/min, p = 0.04). Gal-3 had good performance in predicting “true”-GFR < 60 mL/min; AUC: 0.71, 95%CI [0.58–0.85], best cut off value 17.5 ng/mL. Kaplan–Meier analysis, using median gal-3 (17.5 ng/mL) revealed different survival time for our patients (log-rank p = 0.04). Conclusion: Gal-3 proved trustworthy marker of established chronic kidney disease, with predictive ability in stable decompensated cirrhosis. Gal-3 came also a significant factor for our patients’ outcome. © 2019 Editrice Gastroenterologica Italiana S.r.l.
ER -